RT Journal Article
SR Electronic
T1 The <em>in vitro</em> and <em>in vivo</em> potency of CT-P59 against Delta and its associated variants of SARS-CoV-2
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.07.23.453472
DO 10.1101/2021.07.23.453472
A1 Dong-Kyun Ryu
A1 Hye-Min Woo
A1 Bobin Kang
A1 Hanmi Noh
A1 Jong-In Kim
A1 Ji-Min Seo
A1 Cheolmin Kim
A1 Minsoo Kim
A1 Jun-Won Kim
A1 Nayoung Kim
A1 Pyeonghwa Jeon
A1 Hansaem Lee
A1 Jeong-Sun Yang
A1 Kyung-Chang Kim
A1 Joo-Yeon Lee
A1 Min-Ho Lee
A1 Sang-Seok Oh
A1 Hyo-Young Chung
A1 Ki-Sung Kwon
A1 Soo-Young Lee
YR 2021
UL http://biorxiv.org/content/early/2021/07/23/2021.07.23.453472.abstract
AB The Delta variant originally from India is rapidly spreading across the world and causes to resurge infections of SARS-CoV-2. We previously reported that CT-P59 presented its in vivo potency against Beta and Gamma variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 on the Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal study. CT-P59 showed reduced antiviral activity but enabled neutralization against Delta, Epsilon, and Kappa variants in cells. In line with in vitro results, the mouse challenge experiment with the Delta variant substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against the Delta variant infection, hinting that CT-P59 has therapeutic potency for patients infected with Delta and its associated variants.HighlightsCT-P59 exerts the antiviral effect on authentic Delta, Epsilon and Kappa variants in cell-based experiments.CT-P59 showed neutralizing potency against variants including Delta, Epsilon, Kappa, L452R, T478K and P681H pseudovirus variants.The administration of clinically relevant dose of CT-P59 showed in vivoprotection against Delta variants in animal challenge experiment.Competing Interest StatementThe authors have declared no competing interest.